{
}
Morgan Stanley has upgraded Zealand Pharma to Overweight, citing the long-term potential of its obesity treatment, petrelintide, following a partnership with Roche. Despite current market challenges, analysts believe the obesity market opportunity remains robust, with petrelintide positioned as a leading therapeutic. The recent decline in Zealand's stock price is seen as an attractive entry point for investors, with potential upside from upcoming data and the partnership's implications for future sales.
Barclays has downgraded Rockwool's stock rating from Overweight to Equalweight while maintaining its price target at DKK3,300. The decision follows a significant rise in the company's share price since early 2024, which has limited potential upside. Despite the downgrade, Barclays' financial performance expectations for Rockwool remain unchanged, indicating the stock is now expected to perform in line with market averages.
Danske Bank A/S has announced an extraordinary dividend of DKK 5.35 per share, in addition to an ordinary dividend of DKK 9.35 per share, following its Annual General Meeting on March 20, 2025. The ex-dividend date is set for March 21, 2025. NASDAQ Derivatives Markets will adjust options and futures accordingly.
Danske Bank A/S's annual general meeting did not approve a shareholder proposal to change the dividend payment schedule from annual to quarterly. The bank, Denmark's leading financial institution, operates in various sectors including retail and investment banking, insurance, and asset management. As of the end of 2024, it managed DKK 1,173.8 billion in deposits and DKK 1,074.8 billion in loans.
UBS has maintained a "Buy" rating on Novo Nordisk, setting a target price of 750 Danish kroner. Recent data indicates a decline in initial prescription trends for the company's GLP-1 weight loss drug, Wegovy, in the US market as of March 7, according to analyst Jo Walton.
UBS has maintained a "Buy" rating on Novo Nordisk with a target price of 750 Danish crowns. Recent data indicated a decline in initial prescription trends for Wegovy, the company's GLP-1 weight loss drug, in the US market for the week ending March 7, according to analyst Jo Walton.
Danske Bank A/S has initiated a share buy-back programme totaling DKK 5 billion, aiming to repurchase up to 45 million shares from February 10, 2025, to January 30, 2026. In week 11, the bank acquired 25,000 shares at an average price of DKK 236.1302, bringing the total to 125,000 shares, representing 0.015% of its share capital.
UBS has maintained its "Buy" rating for Novo Nordisk, setting a target price of 750 Danish crowns. Analyst Jo Walton noted a strong recovery in the prescription trend for GLP-1 weight loss drugs, marking the best figures of the year, though she refrained from declaring a definitive trend reversal.
UBS has maintained a 'Buy' rating for Novo Nordisk, setting a target price of 750 Danish crowns. Despite this, the company has recently underperformed compared to Eli Lilly in the initial prescriptions of GLP-1 class weight loss drugs, leading to a slightly disappointing overall development.
UBS has maintained its "Buy" rating for Novo Nordisk, setting a target price of 750 Danish crowns. Analyst Jo Walton noted that Novo Nordisk has recently underperformed compared to Eli Lilly in the initial prescriptions of GLP-1 class weight loss drugs, indicating a slightly disappointing overall development.
Danish Krone
Currency
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Morgan Stanley upgrades Zealand Pharma citing long-term obesity market potential
Euro
Danish Krone
United States Dollar
Zealand Pharma A/S
Hoffmann-La Roche AG
Novo Nordisk A/S
DNK
USA
Show more
09:56 21.03.2025
Barclays downgrades Rockwool stock rating to equalweight while maintaining price target
09:06 21.03.2025
Danske Bank announces extraordinary dividend alongside regular payout for shareholders
17:48 20.03.2025
Danske Bank AGM rejects proposal for quarterly dividend payments
16:57 20.03.2025
ubs maintains buy rating on novo nordisk despite declining wegovy prescriptions
23:34 17.03.2025
ubs maintains buy rating for novo nordisk with target price of 750 crowns
21:07 17.03.2025
danske bank completes week 11 of share buyback program with 25000 shares
10:00 17.03.2025
UBS maintains buy rating for Novo Nordisk with target price of 750 crowns
14:48 07.03.2025
ubs maintains buy rating for novo nordisk with target price of 750 kroner
17:05 03.03.2025
ubs maintains buy rating for novo nordisk with target price of 750 crowns
16:56 03.03.2025
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Banking Regulations
Finance Mergers & Acquisitions
Global Financial Events
Retail and Consumer Goods
CEO Changes
Central Bank Actions
GDP Growth & Recession Forecasts
Global Trade Developments
Market Analysis and Predictions
Industry Mergers & Acquisitions
Financial Scams and Security
Inflation and Monetary Impact
Government Policies
Government Economic Policies
Supply Chain Management
Startups & Entrepreneurship
Workplace Trends
Countries:
Companies:
The Goldman Sachs Group, Inc.
JPMorgan Chase & Co.
Tesla, Inc.
Apple Inc.
Barclays PLC
Bank of America Corporation
Wells Fargo & Company
Citigroup Inc.
Deutsche Bank Money Market PP
Morgan Stanley
Huawei Technologies CO. Ltd.
Lloyds Banking Group plc
Microsoft Corporation
Credit Suisse Strategic Income I
NVIDIA Corporation
Amazon.com, Inc.
AXA SA
Safran SA
Banco Santander, S.A.
Novartis AG
Currencies:
United States Dollar
Euro
Chinese Yuan
British Pound Sterling
Swiss Franc
Japanese Yen
Indian Rupee
Russian Ruble
Australian Dollar
Canadian Dollar
United Arab Emirates Dirham
Indonesian Rupiah
Saudi Riyal
South Korean Won
Danish Krone
Offshore Chinese Yuan
Turkish Lira
Hong Kong Dollar
Mexican Peso
Malaysian Ringgit
People: